drugset / Trial / NCT05964361
First-in-human Interleukin-15-transpresenting Wilms' Tumor Protein 1-targeting Autologous Dendritic Cell Vaccination in Cancer Patients
Phase 1/2
Completed
10 enrolled
University Hospital, Antwerp
Kom Op Tegen Kanker · collabStichting tegen Kanker · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to investigate a new type of dendritic cell vaccine in patients with refractory or advanced solid tumors of the esophagus, liver, pancreas and ovaries. The main questions it aims to answer are: * is it feasible to produce and administer these dendritic cell vaccines? * is treatment with these dendritic cell vaccines safe? Participants will first need to undergo a leukapheresis procedure to collect the cellular starting material for the dendritic cell vaccine production. The treatment consists of 6 vaccines, administered at biweekly intervals. Participants will be followed-up until 90 days after the last vaccine.
Timeline
- Start
- 2023-12-06
- Primary completion
- 2025-09-22
- Completion
- 2025-09-22
Publications
- Background Van den Bergh JM, Lion E, Van Tendeloo VF, Smits EL. IL-15 receptor alpha as the magic wand to boost the success of IL-15 antitumor therapies: The upswing of IL-15 transpresentation. Pharmacol Ther. 2017 Feb;170:73-79. doi: 10.1016/j.pharmthera.2016.10.012. Epub 2016 Oct 21.
- Background Van den Bergh J, Willemen Y, Lion E, Van Acker H, De Reu H, Anguille S, Goossens H, Berneman Z, Van Tendeloo V, Smits E. Transpresentation of interleukin-15 by IL-15/IL-15Ralpha mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity. Oncotarget. 2015 Dec 29;6(42):44123-33. doi: 10.18632/oncotarget.6536.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IL15-transpresenting WT1-targeted Dendritic Cell Vaccine | Vaccine | 8e+06 cells | Other |
| Subject | IL15-transpresenting WT1-targeted Dendritic Cell Vaccine | Vaccine | 1e+07 cells | Other |